Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR4 | Q5NUL3 | 12/20 | 0.41 |
| ▸ | FASN | P49327 | 1/20 | 0.33 |
| ▸ | PAK1 | Q13153 | 1/20 | 0.33 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.33 |
| ▸ | RORC | P51449 | 1/20 | 0.33 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.33 |
| ▸ | PGR | P06401 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.32 |
| ▸ | MME | P08473 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19407282 | 0.92 | FFAR4 (0.39) | FFAR4PAK1RORCTP53MDM2 | |
| SCHEMBL19376942 | 0.91 | FFAR4 (0.35) | FFAR4FASNPAK1RORCTP53 | |
| SCHEMBL19331594 | 0.91 | FFAR4 (0.35) | FFAR4FASNPAK1RORCTP53 | |
| SCHEMBL24428604 | 0.87 | FFAR4 (0.36) | FFAR4 | |
| SCHEMBL19086063 | 0.84 | FFAR4 (0.36) | FFAR4PAK1MME | |
| SCHEMBL16942417 | 0.83 | PAK1 (0.35) | FFAR4FASNPAK1RORCTP53 | |
| SCHEMBL20364010 | 0.83 | PAK1 (0.35) | FFAR4FASNPAK1RORCTP53 | |
| SCHEMBL29813676 | 0.83 | PAK1 (0.35) | FFAR4FASNPAK1RORCTP53 | |
| SCHEMBL19376969 | 0.83 | PAK1 (0.35) | FFAR4FASNPAK1RORCTP53 | |
| SCHEMBL20364026 | 0.83 | FFAR4 (0.36) | FFAR4PAK1MME |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11718591-B2 | Crystalline (2S,4R)-5-(5′-chloro-2′-fluoro-[1,1′-biphenyl]-4-yl)-2-(ethoxymethyl)-4-(3-hydroxyisoxazole-5-carboxamido)-2- methylpentanoic acid and uses thereof | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2023-08-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11718591-B2 | Crystalline (2S,4R)-5-(5′-chloro-2′-fluoro-[1,1′-biphenyl]-4-yl)-2-(ethoxymethyl)-4-(3-hydroxyisoxazole-5-carboxamido)-2- methylpentanoic acid and uses thereof | MME, CTSC, REN | FFAR4 119/4885FASN 2919/4885PAK1 2902/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.